These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8764799)

  • 41. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
    Chew PT; Aung T; Aquino MV; Rojanapongpun P;
    Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group.
    Camras CB; Wax MB; Ritch R; Weinreb R; Robin AL; Higginbotham EJ; Lustgarten J; Stewart WC; Sherwood M; Krupin T; Wilensky J; Cioffi GA; Katz LJ; Schumer RA; Kaufman PL; Minckler D; Zimmerman T; Stjernschantz J
    Am J Ophthalmol; 1998 Sep; 126(3):390-9. PubMed ID: 9744372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
    Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
    Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients.
    Costagliola C; Del Prete A; Verolino M; Antinozzi P; Fusco R; Parmeggiani F; Mastropasqua L
    Graefes Arch Clin Exp Ophthalmol; 2002 May; 240(5):379-86. PubMed ID: 12073061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.
    Diestelhorst M; Krieglstein GK; Lusky M; Nagasubramanian S
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S77-81. PubMed ID: 9154280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
    Sponsel WE; Paris G; Trigo Y; Pena M
    Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
    Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
    Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension.
    Harasymowycz P; Hutnik CM; Nicolela M; Stewart WC
    Can J Ophthalmol; 2007 Feb; 42(1):75-81. PubMed ID: 17361245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes.
    Wang RF; Podos SM; Serle JB; Mittag TW; Ventosa F; Becker B
    Arch Ophthalmol; 2000 Jan; 118(1):74-7. PubMed ID: 10636418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
    Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.
    Alm A; Widengård I; Kjellgren D; Söderström M; Friström B; Heijl A; Stjerschantz J
    Br J Ophthalmol; 1995 Jan; 79(1):12-6. PubMed ID: 7880782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.